Tommy Kenny: Maybe I can answer that, Horst. Currently, it’s the Canadian legislation that prevents us from exporting cannabis products. So unless there is a change in legislation. So we’re permitted under certain exception for medical purposes, but since the U.S. has a very undefined line between medical and consumer, it’s not something that’s permitted for us to export to the U.S. There would be a possibility that we work with the U.S. partner to manufacture it in the U.S. under our brand, but this is not something we can comment on at this point.
Hugh Kelly: Okay. Thank you, Tommy. And one last question then I’ll be quiet. Is there €“ are you partnering with three different animal healthcare companies or is it the original two.
Horst Zerbe: At this point, we have two firm contracts and a third one is being worked on.
Hugh Kelly: Okay. Okay. Thank you. I’ll go back in a queue. Thank you all.
Horst Zerbe: You’re welcome.
Operator: Thank you. And the next question is coming from Trevor Lee. Trevor is a Private Investor. Trevor, your line is live.
Trevor Lee: Hey, how’s gone? I hada quick few questions for you today. Thanks for taking the call. I heard you had a VetaFilm study with the results Q2. Will there be any more studies necessary after that one before commercialization or would that be the last one?
Horst Zerbe: That is a €“ the study that we were €“ that I was discussing or mentioning is a palatability study. And we expect for the key programs that we are working on that the studies will be necessary. That’s €“ these €“ those are just regulatory requirements without those studies, the product wouldn’t be approvable.
Trevor Lee: Okay. Yes. So I was just wondering if there’d be more studies after that one. Would that €“ if that’s
Horst Zerbe: Yes, for sure.
Trevor Lee: Okay. Wondering if you can give an update on like any sort of specific sales numbers for support Spain or CBD products? Like, are you seeing any sort of consistent growth in the CBD or is it kind of leveled off? What is that looking like there?
Horst Zerbe: Andre, do you want to comment?
Andre Godin: Yes, but I mean for RIZAPORT in Spain I think that Horst mentioned that in the introduction that excel this is working on avoiding generic substitution. So that should probably increase the level of sales over there. But there was a peak at first, but now it has declined. So they’re looking at ways to go back on a growing path. So for the CBD, we had a nice order in Q1 and we’re expecting the growth to continue, but we’re not seeing extreme growth at this point. And that’s why we’ve been working on this THC formulation, because we all believe that THC might be more suitable for our technology. But for the time being, it’s pretty steady, but we don’t see that much growth into these product.
Trevor Lee: Yes. And then I think Tommy, for the THC till rate thing, did you say the coming month singular or months plural?
Tommy Kenny: So right now the arbitration is ongoing. I cannot really comment on it. It’s the coming months, several months before we can announce something, but it takes a life of itself. You never know when there could be a resolution earlier, but to manage expectation, we’re looking at several months to be able to announce a resolution and hopefully will be successful in announcing that.
Trevor Lee: Okay. Has there been any talks with atai about any further loans or any sort of share purchasing as part of the original deal or any additional capital coming in from that route?
Andre Godin: Not at the moment, no.
Trevor Lee: Okay.
Andre Godin: But atai still has their option, just to be clear, their option are good for three years. So to some extent, it will also depend on the share price.
Trevor Lee: Okay. And then Dr. Kideckel, if you’re on the call, I was just curious what maybe Horst, if you could clarify what made you guys choose him? And what is you plan to focus on?
Horst Zerbe: I’ll let David speak for himself. David, why don’t you introduce yourself?
David Kideckel: Sure. Thanks. Yes. So, I just joined last week to IntelGenx to lead the Corporate Development Department and really in tandem with the executive team. We’re going to be spearheading an initiative to look for new business development opportunities, while also maintaining the existing business development portfolio, which is why the title actually come strategic alliances. But just quickly to give you a quick background, what I bring to the table is approximately 20 years of combined experience between pharmaceuticals and biotechnology, coupled with capital markets and finance experience. So it’s not really unique blend of the two different worlds, all within life sciences and pharmaceuticals to be able to what we hope will drive shareholder value for IntelGenx.
Trevor Lee: Yes. Is there any other €“ like any kind of strategies that you think IntelGenx has been missing out on or anything different that you would do, I guess, in the future?
David Kideckel: I think this strategy is sound. Again, I’ve only been in the role for about a week now. So, I’m coming up to speed. But I think with the oral film technology and looking at the generic market, one strategy in particular, I think going after those companies, looking at innovator companies and seeing, which products will be going into generic over the next couple of years or so. So so-called low-hanging fruit. I think that’s an area that we could more further develop to target moving forward. And that’s just one example, but there will be others as I .
Horst Zerbe: Maybe I can add to that. We not too long ago, maybe half a year ago, hired another business development person, specifically focusing on our CDMO business. At €“ that person, Mihai has initiated a systematic outreach campaign, has contacted in excess of 100, I think, 130 or so companies where we think that our CDMO services could be used. And he has, in fact, received a pretty interesting feedback. He has initiated concrete program discussions with right now, three companies. So that is a direction that we will keep pursuing with some priority, applying our existing manufacturing and R&D technologies and capabilities to businesses interested in our CDMO services. And just as a side effect, I think I’ve mentioned in the past that our film equipment is also capable of handling transdermal products.
And so one of these CDMO contacts is actually concretely discussing a transdermal program with us. So that’s certainly one focal area in our business development efforts. And a second person in David’s group is looking more closely into animal health. We mentioned two opportunities, and we do see ever increasing interest in applying our film technology to the animal health space.
Trevor Lee: Okay. Nice. I just have a couple more. For the Montelukast, you said enrollment maybe June and then study €“ would that be study results by the end of the year? Or that speed as last dosing by the end of the year?
